Skip to main content
. 2018 May 3;9(2):138–142. doi: 10.1016/j.jtcme.2017.10.005

Table 3.

The Adverse events after treatment with CELcomplex® in the clinical study.

Adverse events Grade 1
Grade 2
Total (average)
6 week (%) 12 week (%) 6 week (%) 12 week (%)
Headache 4.5 4.5 2.4 2.4 3.5
Flatulence 4.5 4.5 4.8 2.4 4.1
GIT-D 4.5 0.0 2.4 4.8 2.9
no side effects 86.5 91.0 90.0 90.0 89.4
Benefits 100.0 100.0 88.0 100.0 97.0

Values are expressed as average, the benefits are epressed as percentuage (*p < 0.05), (**p < 0.01).